Minerva Neurosciences | NERV - Sales Revenues


Minerva Neurosciences reported $0 in Sales Revenues for its fiscal quarter ending in September of 2024.





Sales Change Date
Acadia Pharmaceuticals USD 268.06M 15.94M Mar/2026
Adma Biologics USD 114.5M 24.66M Mar/2026
ALKERMES USD 392.91M 8.41M Mar/2026
Alterity Therapeutics Limited AUD 596.04K 584.66K Dec/2025
AstraZeneca USD 15.29B 213M Mar/2026
BioCryst Pharmaceuticals USD 406.56M 247.16M Dec/2025
Bristol-Myers Squibb USD 11.49B 1.01B Mar/2026
Cipla INR 65.41B 9.77B Mar/2026
Clal Biotechnology ILS 3.41M 2M Dec/2022
Compugen USD 6.35M 60.98M Mar/2026
CSL USD 8.33B 4.79B Dec/2025
Eli Lilly USD 19.8B 500M Mar/2026
Esperion Therapeutics USD 168.45M 81.14M Dec/2025
GlaxoSmithKline GBP 7.63B 991M Mar/2026
Grifols EUR 2B 306.7M Mar/2026
Halozyme Therapeutics USD 377M 74.76M Mar/2026
Ionis Pharmaceuticals USD 246M 43M Mar/2026
J&J USD 24.1B 500M Mar/2026
Merck USD 16.29B 110M Mar/2026
Minerva Neurosciences USD 0 0 Sep/2024
Neurocrine Biosciences USD 811M 5.5M Mar/2026
Novartis USD 13.11B 226M Mar/2026
Novavax USD 147.14M 76.69M Dec/2025
Pfizer USD 14.5B 3.08B Mar/2026
Roche Holding CHF 15.65B 274.5M Dec/2025
Sanofi EUR 11.24B 60M Mar/2026
Takeda JPY 1.09T 100B Mar/2026
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024